What are the precautions for taking Olaparib?

Olaparibis a poly(ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. The recommended dose of olaparib is 300 mg taken orally twice daily, with or without food.

What are the precautions for taking Olaparib(Olaparib)?

1.Myelodysplastic syndrome/Acute myeloid leukemia. Patients who receivedolaparib have developed myelodysplastic syndrome (MDS)/Acute myeloid leukemia (AML), some of which were fatal. Do not initiate olaparib until the patient has recovered from hematologic toxicity (≤Grade 1) from prior chemotherapy. During treatment, monitor complete blood counts for cytopenias at baseline and monthly thereafter for clinically meaningful changes. For long-term hematologic toxicity, interrupt olaparib and monitor blood counts weekly until recovery. If levels have not returned to grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigation, including bone marrow analysis and cytogenetic blood samples. If MDS/acute myeloid leukemia is confirmed, discontinue olaparib.

2.Pneumonia. In a clinical study that enrolled 2901 patients with various cancers who received olaparibmonotherapy, the incidence of pneumonia (including deaths) was 0.8% (24/2901). If a patient develops new or worsening respiratory symptoms, such as dyspnea, cough, and fever, or develops radiological abnormalities, interrupt treatment with olaparib and evaluate the source of symptoms immediately. If pneumonia is confirmed, discontinue olaparib treatment and treat the patient appropriately.

3.Venous thromboembolism. Venous thromboembolism (VTE), including severe or fatal pulmonary embolism (PE) occurred in patients receiving linolaparib. Monitor patients for clinical signs and symptoms of venous thrombosis and pulmonary embolism and institute appropriate medical treatment, including long-term anticoagulation as clinically indicated.

4.Embryo-Fetal Toxicity. According to Olaparib’s mechanism of action and animal test results, taking Olaparib by pregnant women may cause harm to the fetus. In an animal reproduction study, olaparib administration to pregnant rats during organogenesis resulted in teratogenic and embryo-fetotoxicity at exposures lower than the recommended human dose of 300 mg twice daily. Inform pregnant women of potential harm to the fetus and potential risks of miscarriage. Advise women of childbearing potential to use effective contraception during treatment and for 6 months after the last dose of olaparib. Based on the results of genotoxicity and animal reproduction studies, it is recommended that male patients with female partners or pregnant male patients use effective contraception during treatment and for 3 months after the last dose of olaparib. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0